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Summary From 1984 to 1989, 63 patients with diffuse, malignant mesothelioma of the pleura were treated
with 4-8 courses of high-dose methotrexate (HDMTX, 3 g total dose) and citrovorum factor rescue. There
were 61 male and two female patients of median age 60 years. CT scan was performed before and after
treatment and used for response evaluation. Of 60 patients evaluable for response, 37% showed partial or
complete remission, 32% showed no change and 32% showed progressive disease. Median survival from start
of treatment for all patients was 11 months, for 42 patients with the epithelial type 12 months, and for 20
patients with sarcomatous or mixed types only 5 months. Toxicity was acceptable, with only five patients (8%)
terminating therapy due to toxicity. One toxic death occurred. We conclude that HDMTX is an active regimen in malignant pleural mesothelioma. The significantly shorter survival for patients with the sarcomatous or
mixed subtypes indicates that further investigations on the activity of HDMTX in mesothelioma should be
limited to patients with the epithelial subtype.
The outlook for patients with malignant mesothelioma of the
pleura is generally extremely poor, with median survival rates
around 12 months or less (Alberts et al., 1988). Local treat-
ment with surgery, radiotherapy or systemic chemotherapy
has so far been unsuccessful in improving this situation
(Brenner et al., 1982). However, some reports on small
numbers of patients indicate that some cytotoxic drugs may
be active (Aisner and Wiernik, 1981; Falkson et al., 1988).
Methotrexate has been regarded as one of these agents,
especially when given in escalated doses (Dimitrov et al.,
1982). The number of patients treated has however been too
small for definite confirmation of activity or inactivity. This
report addresses the results of high-dose methotrexate
(HDMTX) treatment in a relative large series of patients.
Material and methods
Patients
Following the initial report of Dimitrov et al. (1982) on
HDMTX therapy of malignant mesothelioma, a phase II
trial was initiated in our institution to study the effect of
chemotherapy with HDMTX in this disease. From 1984 to
1989, a total of 73 patients with malignant pleural meso-
thelioma were admitted to our institution; 70 male and three
female. Their age distribution is shown in Figure 1. Median
age at diagnosis was 60 years (range 39-76 years). Fifty-nine
patients (81%) reported some degree of previous exposure to
asbestos, and 54% had been repeatedly exposed in their
occupation for prolonged periods of time (Table I).
Patients were eligible for the HDMTX study if they had
histologically proven malignant mesothelioma of the pleura,
symptomatic disease in need of palliative treatment, Karnof-
sky index > 50, no evidence of mestastases to the central
nervous system, and normal renal function as judged by
serum creatinine. Of the 73 patients admitted during the
study period, eight patients were excluded due to a Karnof-
sky index <50, and one patient with very slowly progressing
disease and minimal symptoms was treated by irradiation of
an implantation metastasis only. HDMTX treatment was
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Figure 1 Age distribution in 63 patients treated with HDMTX
for malignant pleural mesothelioma.
Table I Previous asbestos exposure
Degree ofasbestos exposure Number ofpatients Per cent
Heavy 11 15.1
Moderate 28 38.4
Slight 20 27.4
None 12 16.4
Unknown 2 2.7
Degree of occupational asbestos exposure in all 73 patients with
malignant pleural mesothelioma admitted to The Norwegian Radium
Hospital from 1984 to 1989.
given to one patient where the diagnosis of mesothelioma
was made on the basis of aspiration cytology. This patient is
excluded for response and survival analysis, but is included in
the analysis of toxicity. Thus, a total of 63 patients treated
with HDMTX form the basis of the present report.
Histological sections
These were reviewed by one expert pathologist (A.E.S.) prior
to the start of therapy in all cases. Tumour tissue was
obtained by thoracotomy or thoracoscopy in 34 patients, by
several thick needle biopsies (Abrams) in 23, and by several
biopty cut biopsies in six. In cases where the pathology
review was inconclusive, the patient was re-biopsied for firm
establishment of the diagnosis. Apart from standard Haema-
toxylin/Eosin staining, Alcian green staining, carcinoembry-
onal antigen (CEA) immunohistochemistry and electron
microscopy were used electively to aid diagnosis.
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Computerised tomography
Computerised tomography of the chest and upper abdomen
was performed before start oftreatment. The thickness of the
sections was 5 mm and the spacing 10 mm. As contrast
medium, 50 ml Iohexol 300 mgml ' was injected as bolus
followed by infusion of 200 ml lohexol 140 mg ml-'.
For evaluation of response, the examination was repeated
3 weeks after the fourth methotrexate infusion and, for
patients continuing treatment, 3 weeks after the eighth
infusion. For each patient every CT image was compared
with the corresponding image from the previous examination.
To ensure identical localisation of CT images, anatomical
landmarks in vertebrae, ribs or the central bronchial tree
were used during the CT scanning procedure. The thickness
of the tumourous parietal, visceral, diaphragmatic, and medi-
astinal pleura was measured together with any enlarged
lymph nodes in the mediastinum, rectrocural space or axillae.
Care was taken to distinguish tumour from organised pleural
fluid and lung atlectasis. Accumulation of contrast medium
was used to aid the distinction between tumour and benign
pleural thickening.
The staging system
This was similar to that proposed by Butchart et al. (1976):
Stage I: Tumour confined to the pleura of one hemithorax.
Stage II: Tumour invading the chest wall or involving
mediastinal structures. Enlargement of mediastinal lymph
nodes to a diameter of more than 1.5 cm.
Stage III: Tumour penetrating diaphragm to involve peri-
toneum. Involvement of the opposite pleura, lymph node
enlargement outside the chest or penetration by tumour
through the chest wall.
Stage IV: Distant metastases.
Treatment response
The growth pattern of pleural mesothelioma is diffuse, and
the tumour often invades most or all of the pleural surface of
one hemithorax. CT scans of such a patient are shown in
Figure 2. Conventional WHO criteria for tumour measure-
ment and response evaluation, requiring the identification of
two perpendicular tumour diameters, are unsuitable for the
evaluation of tumour 'size' in this disease. If these criteria
were to be employed in mesothelioma, the majority of
patients would be ineligible for the study of treatment res-
ponse, and reported results would represent only a small,
highly selected group of patients. We are not aware of any
recommended alternative system for response evaluation suit-
able for malignant mesothelioma.
Multiple studies have concluded that CT scanning is the
method of choice for tumour evaluation in this disease, as
reviewed by Whitley (1987). The superiority of CT scan over
conventional chest X-ray is also clearly evident from Figure
2. Thus, in the present study, tumour response was evaluated
by CT scans according to the following definitions:
Progressive disease: Increase of tumour thickness in three
sections by 30% or more, or in two sections by 50% or
more. Appearance of regional (usually mediastinal) or distant
metastases.
Partial remission: Corresponding decrease in tumour thick-
ness (as illustrated in Figure 2), without appearance of
regional or distant metastases.
Complete remission: No evidence of disease by CT.
No change: Any situation not fulfilling the above criteria.
Changes in the amount of pleural fluid present were not
included in the response evaluation, and care was taken not
to interpret reduced atelectasis after pleural drainage as
tumour shrinkage.
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Figure 2 Chest X-rays and CT scans of 48 year old male patient with epithelial malignant mesothelioma in the right hemithorax.
The patient was evaluated at the start of HDMTX treatment (A and B) and following four HDMTX courses (C and D). The
patient demonstrated a partial response to the treatment. The figure clearly illustrates the superiority of CT over chest X-ray in the
evaluation of this disease.958 0.P. SOLHEIM et al.
Treatment
Before the methotrexate infusion, prehydration with 200 ml
NaHCO3 (500 mmol 1') in 300ml- NaCl was given over
30 min. Methotrexate was administered as a 16 h infusion
with a standard dose of 3 g in 1,000 ml NaHCO3. All
HDMTX courses in this study were given with this dose,
without dose modifications. Hydration was carried out with a
minimal fluid intake of 2,500mlm-2 day-' and a minimal
fluid output of 2,000mlm-2 day-'. For urine alkalinisation
3 g NaHCO3 was given every 6 h, and with increased doses if
urinary pH fell below 7.0. Citrovorum factor (CF) rescue was
initiated 24 h after start of MTX infusion with 15 mg every
6 h, until the serum MTX concentration fell below 80 nmol
1-1 (0.8 x 10-7 M), after which the patients were discharged
from hospital. The number of CF doses were adjusted accord-
ing to the serum MTX concentration, and the minimum
number of CF doses was 11.
The first four infusions were given with 10 day intervals.
Response was evaluated 3 weeks later. Patients showing res-
ponse (or no change, but with subjective improvement), con-
tinued treatment with four additional infusions, administered
with 21 day intervals.
In the later course of the disease some patients were
treated with additional HDMTX, weekly doxorubicin or by
palliative irradiation.
Results
All patients were symptomatic (shortness of breath and/or
pain). The onset of these symptoms were usually gradual and
could not be defined accurately. As a measure of the interval
before start of treatment we thus registered the time interval
from the first chest X-ray showing pleural tumour to start of
treatment. The median time was 4 months (range <1-16
months). Six of the 63 patients (10%) had been under obser-
vation for more than 12 months before increasing symptoms
made active treatment necessary.
Histology
Forty-two patients (68%) had the epithelial type of malig-
nant mesothelioma, 16 (26%) had the mixed type, and four
(6%) had the sarcomatous type. One tumour could not be
subclassified. Histochemical carcinoembryonic antigen (CEA)
staining was negative in all 23 cases examined.
Cytological examination of pleural fluid was carried out in
48 cases, but gave the diagnosis in only ten (21%).
Computerised tomography
The extension and thickness of the pleural tumour at the
start of the treatment is summarised in Table II. The pleural
lining the chest wall was involved in all cases. Most patients
also had involvement of the diaphragmatic, mediastinal,
pericardial, and interlobar pleura. Approximately one third
of the patients had a tumour thickness regarded as 'slight'
(<10 mm), and 90% had stage I or II disease as defined by
Butchart et al. (1976) (Table III).
Various degrees of constriction of the diseased hemithorax
was observed in 92%. Compressed or atlectatic lung tissue
Table III Stage at start of treatment
Stage Number ofpatients Per cent
I 38 60
II 19 30
III 6 10
IV 0 0
Staging by CT scan in 63 patients treated with HDMTX. Stages are
according to Butchart et al. (1976).
was present in 87%, and pleural fluid in 84%. Only two
patients showed infiltration through the mediastinum with
involvement of the opposite pleura, while 23 patients had
plaques or other benign thickening of the opposite pleura.
Twenty-five per cent of the patients had pathological lymph
nodes in the mediastinum, and 20% showed direct
infiltration into the mediastinum.
Although many patients showed infiltration very deep into
the pleural sinus, penetration to the abdominal cavity with
peritoneal involvement was observed in only three cases.
Infiltration through the chest wall had occurred in 15 cases,
ofwhich at least five had implantation metastases in the path
of previous pleural drainage.
Laboratory tests
At the time of diagnosis, the number of platelets were
elevated above 400 x 109 I- in 34 of the 64 patients (53%).
CEA in serum was within the normal range in 23 of the 25
tested patients. The remaining two patients showed mar-
ginally elevated levels. Increased serum concentrations of
hyaluronate, a tumour marker for mesothelioma (Dahl &
Laurent, 1988, Dahl et al., 1989), were found in 28 of the 50
patients studied (56%). Substantially elevated levels of
hyaluronate were found in the pleural fluid in all 13 cases
studied.
Tumour response
Three patients were. not evaluable for tumour response. One
of these suffered a toxic death during the second HDMTX
course, one patient had only one HDMTX course due to
toxicity, and one patient was withdrawn from further
HDMTX therapy after only one course (by his local hos-
pital), and was subsequently lost to follow-up. Ofthe remain-
ing 60 patients, 37% showed objective tumour response, 32%
showed no change, and 32% showed progressive disease
(Table IV). Median response duration was 7.5 months (range
4-70 + months), and median duration of stable disease was
Table IV Response to treatment with HDMTX
Number ofpatients Per cent
Progressive disease 19 32
No change 19 32
Partial remission (PR) 21 35
Complete remission (CR) 1 2
Not evaluable 3
Treatment response in 63 patients treated with HDMTX. Overall
response rate (PR + CR) is 37%.
Table II Tumour localisation and thickness of pleural tumour
Tumour thickness
Tumour site Slight Moderate Heavy No. ofpatients
(pleura) None <10mm 10-25mm >25mm Unknown with tumour (%)
Chest wall 0 28 25 9 1 62 (86)
Mediastinal 6 32 18 6 1 56 (78)
Pericardial 9 36 13 4 1 53 (74)
Interlobular 7 40 13 2 1 55 (76)
Diaphragmatic 1 36 16 7 3 59 (83)
Numbers designatenumbers ofpatients(percentofall). Tumourthicknesswasconfirmedinat
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10 months (range 2-31 + months). Pleural fluid and pain
were commonly reduced, also in patients showing no change
in tumour size. There was no evidence of differences in
response rates between the different histological subtypes,
and the response rate was not correlated to the extent of
disease by Butchart staging. However, the numbers of
patients in the different sub-groups were too small for such
comparisons.
Survival
The actuarial survival for all 63 patients is shown in Figure
3. Fifty-four patients have died during the study period,
median observation time for the nine patients still alive was
37 months (range 17-70 months). Median survival for all
patients was 11 months, with patients with the epithelial type
doing significantly better (median survival 12 months) than
patients with mixed or pure sarcomatous types (5 months,
P = 0.001, log-rank test). After 2 years, 32% of the patients
with the epithelial type were alive. In contrast, only one
patient (5%) with the sarcomatous/mixed type was alive after
2 years.
Toxicity
In 27 of the patients (42%), no toxicity was recorded. In 27
others, low-grade toxicity in the form of mild nausea, sto-
matitis or conjunctivitis was noted, these episodes did not
interfere with the treatment plan.
Delayed MTX excretion was observed in six patients (9%).
In these cases, serum MTX concentrations reached 80 nmol
1' after 9, 8, 6, 5, 5 and 5 days respectively. The delay
occurred after the first MTX infusion in three patients, and
after the third to seventh infusion in the other three. The
incidents led to termination of MTX treatment for five of
these six patients. No evidence was found suggesting that
pleural fluid acting as a 'third compartment' contributed to
delayed MTX excretion. These incidents were generally cor-
related with moderate and transient rises in serum creatinine,
pointing to a pre-treatment reduction in renal function or
direct renal MTX toxicity as the most likely causes of
delayed MTX clearance.
One patient developed an allergic/toxic reaction which
started on the second day after his first MTX infusion, with a
generalised exanthema and an increase in serum creatinine.
On the third day pneumonitis became evident. The excretion
of MTX was not delayed, and the symptoms disappeared
gradually. Subsequently, seven HDMTX courses were admin-
istered without complications.
One toxic death occurred. This was a 60 year old man with
stage III disease, who developed exanthema and pneumonitis
5 h after start of his second MTX infusion. The infusion was
immediately stopped. Fever appeared on the second day.
Complete bone marrow failure ensued, and the serum crea-
tinine level increased steadily until death on the sixth day.
Post mortem examination showed tumour infiltration in the
chest wall, pericardium and mediastinum, and the bone mar-
row was aplastic.
Discussion
In our series of patients the distribution of age, asbestos
exposure, histological type, and stage are similar to that in
most other reports (Alberts et al., 1988; Antman et al., 1988),
making it unlikely that the selection of patients in this
material has been biased with regard to chemosensitivity.
In 1982, Dimitrov et al. reported the effects of HDMTX in
nine patients with malignant mesothelioma. Of six patients
with pleural disease, three showed complete remission and
two showed partial response. Although these results are often
quoted in the more recent literature (Alberts et al., 1988;
Talcott & Antman, 1988), we are not aware of any other
reports on HDMTX therapy of malignant mesothelioma.
Due to the diffuse growth of pattern of pleural meso-
thelioma, the tumour extension is difficult to evaluate accord-
ing to classical WHO criteria. We therefore chose to apply
tumour thickness as measured by CT scanning as our res-
ponse parameter, this providing a specific tumour mea-
surement. In most other reports, the method employed for
tumour measurement is poorly documented (Colbert et al.,
1985; Mintzen et al., 1985; Raghavan et al., 1990; Sorensen
et al., 1985). This makes it difficult to directly compare our
results with those of others, and it is equally difficult to
compare the results of previous studies with each other. The
main intention of the present study was thus to investigate
whether or not HDMTX is an active regimen in malignant
mesothelioma, rather than to compare its activity with that
of previously tested agents.
Due to the difficulty in response evaluation in mesothe-
lioma, the effect of treatment on subsequent survival is of
particular importance. Median survival in the present series is
comparable to that reported in several other series (Alberts et
al., 1988; Antman et al., 1988; Brenner et al., 1982), i.e. 11
months for the group as a whole, 12 months for patients with
epithelial type, and only 5 months for patients with sar-
comatous or mixed types (Figure 3). Some epithelial meso-
theliomas are known to have a slow natural growth rate.
Studies of untreated patients have thus shown prolonged
survival for 10-15% of patients (Law et al., 1984). A slow
natural growth rate may also explain why, in our study,
stable disease on average lasted longer (median 10 months)
than the objective responses (7.5 months). Thirty-two per
cent of the patients with the epithelial type survived for more
than 2 years, and 18% survived for more than 3 years. This
may suggest a possible effect of HDMTX on survival in this
histological subgroup. Due to disease progression following
HDMTX treatment, 18 patients were subsequently treated
with doxorubicin, and nine were treated with palliative
radiotherapy. Whether this therapy may have contributed to
improved survival remains unknown.
Despite the high age of most patients and the presence of
significant amounts of pleural fluid, the treatment with
HDMTX did not result in unacceptable toxicity. However,
we emphasise that the chemotherapy protocol was followed
meticulously, and that the patients were monitored carefully
during the MTX excretion phase.
In conclusion, high dose methotrexate is an active regimen
in the treatment of patients with diffuse malignant mesothe-
lioma of the pleura, as shown by an objective response rate
of 37%. With careful monitoring of the patients, the treat-
ment is safe for patients less than 80 years old in fair
condition. Considerable amounts of pleural fluid is not a
contraindication to treatment with HDMTX. Due to an
indication of short response duration and poor survival in
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Figure 3 Actuarial overall survival for patients treated with
HDMTX for malignant pleural mesothelioma, according to his-
tological type. ( ), all patients, n = 63. (---), epithelial type,
n = 42. (.... ), sarcomatous or mixed type, n = 20. Time is from
the start of HDMTX treatment. The survival difference between
patients with epithelial and sarcomatous/mixed types is statis-
tically significant (P = 0.001, Log-rank test).
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patients with sarcomatous or mixed histological subtypes, the
treatment should possibly be reserved for patients with the
epithelial type of mesothelioma. However, this finding needs
verification in a larger number of patients. It should also be
emphasised that the response rate reported in this series
should be interpreted with caution, as mesothelioma is a
difficult disease to evaluate, necessitating novel methods for
tumour measurement. Randomised studies are required to
establish whether HDMTX treatment can improve survival
for these patients. Considering the cost of HDMTX therapy,
the demonstration of a survival benefit seems necessary for
the justification of HDMTX as routine treatment for meso-
thelioma. Finally, the optimal dosage and treatment duration
also remain to be established.
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